HRMY Overview

Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is43.83 USD with a low forecast of 32.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Harmony Biosciences Holdings Inc revenue for the last quarter amounts to 243.78M USD, increased 21.12

Harmony Biosciences Holdings Inc. EPS for the last quarter amounts to 0.39 USD, decreased -54.12

Harmony Biosciences Holdings Inc (HRMY) has 293 emplpoyees as of March 12 2026.

Today HRMY has the market capitalization of 1.67B USD.